Short-term effect and its retention of LSVT®BIG on QOL improvement: 1-year follow-up in a patient with Parkinson's disease

Yuichi Hirakawa, Soichiro Koyama, Kazuya Takeda, Masanobu Iwai, Ikuo Motoya, Hiroaki Sakurai, Yoshikiyo Kanada, Nobutoshi Kawamura, Mami Kawamura, Shigeo Tanabe, Shigeo Tanabe

Research output: Contribution to journalArticlepeer-review

Abstract

BACKGROUND: There are no reports regarding the long-term retention of effects of Lee Silverman Voice Treatment® BIG (LSVT® BIG) on improvements in quality of life (QOL) among patients with Parkinson's disease (PD). OBJECTIVE: This study aimed to evaluate the short-term effect of LSVT® BIG on QOL improvement and its retention in a patient with PD. Motor symptoms, walking ability, and walking speed were evaluated as factors associated with QOL. METHODS: A 63-year-old woman who was diagnosed with PD received a 4-week LSVT® BIG program under the supervision of certified LSVT® BIG physical therapists. The participant's disease severity was classified as Hoehn and Yahr stage 2. The Parkinson's Disease Questionnaire-39 (PDQ-39), Movement Disorder Society-sponsored Unified Parkinson's Disease Rating Scale (MDS-UPDRS) part 3, timed up-and-go test (TUG), and 10m walk test (10 MWT) were evaluated before, after, and 1-year after the intervention. RESULTS: The results indicated short-term improvements in the PDQ-39, MDS-UPDRS part 3, TUG, and 10 MWT which were retained for up to 1 year. CONCLUSIONS: This case report suggests the possibility of 1-year retention of improvements in QOL, motor symptoms, walking ability, and walking speed resulting from LSVT® BIG intervention in a patient with mild PD.

Original languageEnglish
Pages (from-to)501-509
Number of pages9
JournalNeuroRehabilitation
Volume49
Issue number3
DOIs
Publication statusPublished - 2021

All Science Journal Classification (ASJC) codes

  • Physical Therapy, Sports Therapy and Rehabilitation
  • Rehabilitation
  • Clinical Neurology

Fingerprint

Dive into the research topics of 'Short-term effect and its retention of LSVT®BIG on QOL improvement: 1-year follow-up in a patient with Parkinson's disease'. Together they form a unique fingerprint.

Cite this